Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alison D Parisian"'
Autor:
Tomoyuki Koga, Isaac A. Chaim, Jorge A. Benitez, Sebastian Markmiller, Alison D. Parisian, Robert F. Hevner, Kristen M. Turner, Florian M. Hessenauer, Matteo D’Antonio, Nam-phuong D. Nguyen, Shahram Saberi, Jianhui Ma, Shunichiro Miki, Antonia D. Boyer, John Ravits, Kelly A. Frazer, Vineet Bafna, Clark C. Chen, Paul S. Mischel, Gene W. Yeo, Frank B. Furnari
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
The dearth of glioblastoma model systems that accurately recapitulate the disease remains a challenge. Here, the authors develop cancer avatars using genetically engineered human induced pluripotent cells.
Externí odkaz:
https://doaj.org/article/129339bec1d846d6beb84462802c2cb9
Autor:
Alison D. Parisian, Gopinath S. Palanisamy, Fabian Ortega, Judevin L. Sapugay, William J. Bodell, David Kulp, Peter Kushner, Cyrus Harmon
Publikováno v:
Cancer Research. 83:P2-24
OP-1250, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), is currently in Phase I/II clinical trials for the treatment of estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negati
Autor:
Shayesteh R Ferdosi, Brett Taylor, Matthew Lee, Nanyun Tang, Sen Peng, Rita Bybee, George Reid, Lauren Hartman, Krystine Garcia-Mansfield, Ritin Sharma, Patrick Pirrotte, Jianhui Ma, Alison D Parisian, Frank Furnari, Harshil D Dhruv, Michael E Berens
Publikováno v:
Neuro-Oncology. 24:1857-1868
Autor:
Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner
Publikováno v:
Cancer Research. 82:P5-08
The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) oncogene is overexpressed in approximately 25% of breast cancer tumors and is associated with a high rate of brain metastasis. Patients with brain metastases have a poor prognos
Autor:
Shunichiro Miki, Tomoyuki Koga, Andrew M Mckinney, Alison D Parisian, Takahiro Tadokoro, Raghavendra Vadla, Martin Marsala, Robert F Hevner, Joseph F Costello, Frank Furnari
Publikováno v:
Neuro-oncology, vol 24, iss 12
Neuro Oncol
Neuro Oncol
Background Heterozygous TERT (telomerase reverse transcriptase) promoter mutations (TPMs) facilitate TERT expression and are the most frequent mutation in glioblastoma (GBM). A recent analysis revealed this mutation is one of the earliest events in g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6649bf537ce52f39e5a4f08689b24124
https://escholarship.org/uc/item/0jg0f4pz
https://escholarship.org/uc/item/0jg0f4pz
Autor:
Tomoyuki Koga, Isaac A. Chaim, Jorge A. Benitez, Sebastian Markmiller, Alison D. Parisian, Robert F. Hevner, Kristen M. Turner, Florian M. Hessenauer, Matteo D’Antonio, Nam-phuong D. Nguyen, Shahram Saberi, Jianhui Ma, Shunichiro Miki, Antonia D. Boyer, John Ravits, Kelly A. Frazer, Vineet Bafna, Clark C. Chen, Paul S. Mischel, Gene W. Yeo, Frank B. Furnari
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-1 (2020)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://doaj.org/article/d9b1f48e7feb41caa2018a9b105745a1
Autor:
Frank Furnari, Shunichiro Miki, Tomoyuki Koga, Andrew M Mckinney, Alison D Parisian, Takahiro Tadokoro, Raghavendra Vadla, Martin Masala, Robert F Hevner, Joseph F Costello
Publikováno v:
Neuro-Oncology Advances. 4:iii27-iii28
Heterozygous TERT (Telomerase reverse transcriptase) promoter mutations (TPMs) facilitate TERT expression and are the most frequent mutation in glioblastoma (GBM). A recent analysis revealed this mutation is one of the earliest events in gliomagenesi
Autor:
Alison D. Parisian, Caitlin Miller, Fabian Ortega, Leslie Hodges-Gallagher, Susanna Barratt, Joey Azofeifa, Peter J. Kushner, David Kulp, Cyrus L. Harmon
Publikováno v:
Cancer Research. 82:5375-5375
OP-1250 is an orally-bioavailable complete estrogen receptor antagonist (CERAN) previously shown to shrink wild-type and Y537S mutant estrogen receptor-positive (ER+) tumors in multiple preclinical xenograft models. To better understand the effects o
Autor:
S R. Ferdosi, B Taylor, M Lee, N Tang, S Peng, R Bybee, G Reid, L Hartman, K Garcia-Mansfield, R Sharma, P Pirrotte, Jianhui Ma, Alison D Parisian, F Furnari, HD Dhruv, ME Berens
Finding and matching drugs to treat subsets of cancers remains a daunting challenge of precision medicine. Neddylation inhibition, affecting posttranslational protein function and turnover, is a promising therapeutic approach to cancer including glio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::124b5cf97611dbb9c1332144e7966a52
https://doi.org/10.1101/2020.07.21.212571
https://doi.org/10.1101/2020.07.21.212571
Autor:
Pamela M. Klein, Alison D. Parisian, Leslie Hodges-Gallagher, Richard Sun, Peter J. Kushner, David C. Myles, Cyrus L. Harmon
Publikováno v:
Cancer Research. 81:LB122-LB122
Estrogen receptor-positive (ER+) breast cancer can undergo metastatic spread to the brain, which occurs in up to 15% of HER2-/ER+ metastatic breast cancer patients. Although endocrine therapy is not explicitly approved for brain metastasis and clinic